Van Leeuwen & Company, LLC Abb Vie Inc. Transaction History

Van Leeuwen & Company, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Feb 06, 2024	BUY	$144.61 - $166.54 $2.77 Million - $3.19 Million	19,155 New	19,155 $3.05 Million
Q1 2023 May 08, 2023	BUY	$144.61 - $166.54 $2.77 Million - $3.19 Million	19,155 New	19,155 $3.05 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $2.09 Million - $2.38 Million	-19,683 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $2.07 Million - $2.31 Million	19,683 New	19,683 $2.25 Million
Q1 2019 May 15, 2019	SELL	$77.14 - $90.79 $254,253 - $299,243	-3,296 Closed	0 $0
Q4 2018 Mar 13, 2019	BUY	$77.85 - $96.01 $10,120 - $12,481	130 Added 4.11%	3,296 $304,000
Q3 2018 Mar 13, 2019	BUY	$88.91 - $98.84 $281,489 - $312,927	3,166 New	3,166 $299,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Van Leeuwen & Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Van Leeuwen & Company, LLC with notifications on news.